In vivo CYP3A activity in palliative care patients
- Conditions
- In vivo CYP3A activity in palliative care patients
- Registration Number
- DRKS00011753
- Lead Sponsor
- niversitätsklinikum Heidelberg, Klinik für Anäthesiologie
- Brief Summary
Results: Partial metabolic clearance of midazolam in palliative care patients was 31.7 ± 32.1 L/h. This was a highly significant 40% reduction (p < 0.0001) in comparison with the cytochrome P450 3A activity of healthy subjects. Conclusion: Dosing of cytochrome P450 3A substrate drugs (e.g. macrolide antibiotics, benzodiazepines, calcium channel blockers) needs to be adjusted in palliative care patients; otherwise, escalation of debilitating symptoms due to drug interactions might occur.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 41
Every patient admitted on the ward who is at least 18 years of age could be enrolled. Hemoglobin should be >7.5 g/dL.
Exclusion criteria are the need of red blood cells transfusions on a regular basis, inability to communicate well with the investigator due to language problems or poor mental development
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This study aims to find out how the CYP3A activity is in individual patients with various genetic predisposition and specific underlying diseases on a palliative care unit during real clinical conditions in comparison to healthy volunteers or other patients.
- Secondary Outcome Measures
Name Time Method Secondary outcome of this study is to find out if dose adjustment for palliative care patients is necessary if CYP3A inductors or inhibitors are combined with CYP3A substrates?